Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02223819
Title Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center, Pfizer
Indications

necrotic uveal melanoma

mixed cell uveal melanoma

posterior uveal melanoma

uveal melanoma

Therapies

Crizotinib

Age Groups: adult
Covered Countries USA


No variant requirements are available.